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1. Introduction
Food allergy (FA) is an increasing public health problem 
(Berin and Sampson, 2013). Cow’s milk allergy (CMA) 
is one of the most common FA in early childhood, with 
an estimated prevalence ranging between 2 and 3% in 
infants (Apps and Beattie, 2009). During the last decade, 
we observed a changing pattern in FA with increased 
prevalence, severity of clinical manifestations and risk 
of persistence until later ages. The Centers for Disease 
Control and Prevention documented an 18% increase 
among children in the USA between 1997 and 2007. In 
the same country, FA accounts for about 30,000 emergency 
room visits and 150 deaths per year (http://foodallergy.org). 
Similarly, in Italy we observed that the number of hospital 
admissions for food-induced anaphylaxis doubled in only 
5 years, and that cow milk proteins were the leading food 
allergens (Berni Canani et al., 2012a). There is evidence that 
resolution rates have slowed for allergies that have been 
commonly outgrown, such as those to milk, egg, wheat and 
soy. For example, Elizur et al. (2012) in a population-based 
study reported that only 57.4% of CMA children resolved 
their allergy at 5 years of age. FA has deleterious effects 
on family economics, social interactions, school and work 
attendance, and health-related quality of life; it can be 
costly in terms of medical visits and treatments (Sicherer 
and Sampson, 2014). Given the morbidity resulting from 
FA, there is considerable interest in generating efficient 
approaches that may stimulate oral tolerance acquisition 
and maintenance. Rising disease prevalence over a short 
period of time cannot be explained by genetic variation 
alone, renewing interest in the role of the environment in 
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Abstract
Food allergy (FA) is a major health issue for children living in Western countries. At this time the only proven 
treatment for FA is elimination of offender antigen from the diet. It is becoming clear that the development of 
gut microbiota exerts a profound influence on immune system maturation and tolerance acquisition. Increasing 
evidence suggests that perturbations in gut microbiota composition of infants are implicated in the pathogenesis 
of FA. These findings have unveiled new strategies to prevent and treat FA using probiotics bacteria or bacterial 
substance to limit T-helper (Th)/Th2 bias, which changes during the disease course. Selected probiotics administered 
during infancy may have a role in the prevention and treatment of FA. Lactobacillus rhamnosus GG (LGG) is the 
most studied probiotic in this field. Administration of LGG in early life have a role in FA prevention. Preliminary 
evidence shows that LGG accelerates oral tolerance acquisition in cow’s milk allergic infants. We are understanding 
the mechanisms elicited by LGG and metabolites in influencing food allergen sensitization. A deeper definition of 
these mechanisms is opening the way to new immunotherapeutics for children affected by FA that can efficiently 
limit the disease burden.
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shaping allergic sensitisation to food. As our knowledge of 
the crucial influence of gut microbiota on the maturation of 
immune system has grown, more recent evidences support 
the idea that alterations of gut microbiota composition 
induced by environmental factors (e.g. antibiotics, diet, 
sanitation) may play a central role in the occurrence of FA. 
At the same time, increasing evidence indicates development 
of gut microbiota as a crucial factor for immune system 
maturation and tolerance acquisition (Gourbeyre et al., 
2011). These data support the use of probiotics, defined 
as live microorganism that when consumed in adequate 
amounts as part of food or as oral supplements confer a 
health benefit on the host (Hill et al., 2014), as potential 
preventive and therapeutic strategy for FA. Lactobacillus 
rhamnosus GG (LGG) is the probiotic formulation most 
often associated with clinical efficacy in FA. In this paper, 
we discuss the most recent evidences that support the role 
of probiotics, and in particular of LGG, in the prevention 
and treatment of FA.
2. Microbiota as potential target for food allergy
The crucial role of gut microbiota in the pathogenesis of 
FA is supported by several lines of evidence deriving from 
clinical and basic science studies. The more recent and 
relevant evidences are the following.
Dysbiosis
Imbalance in intestinal microbiota composition has been 
documented in patients with FA. Ling et al. (2014) showed 
that several key FA-associated bacterial phylotypes, but 
not the overall gut microbiota diversity, significantly 
changed in infants with FA. Nakayama et al. (2011) 
profiled the faecal bacteria compositions in allergic and 
non-allergic infants using the 16S rRNA gene short-tag 
pyrosequencing approach and correlated some anomalies 
in the microbiota with allergy development in later years. 
The comparative analysis of genus-level composition data 
identified population differences in some genera between 
the allergic and non-allergic groups. Interestingly, allergic 
infants showed high colonisation of Bacteroides and/or 
Klebsiella and less colonisation of Clostridium perfringens/
butyricum, suggesting antagonism between these bacterial 
groups in the gastro-intestinal tract (Nakayama et al., 2011). 
This finding is apparently in contrast with previous studies 
in which Clostridia were more abundant in allergic infants 
(Kalliomaki et al., 2001a,b; Smehilova et al., 2008). This 
discrepancy may be attributable to species differences, 
because Clostridia contain a wide number of different 
bacterial strains. Reduced microbial encounter has been 
hypothesised to play a role in the development of allergies. 
Caesarean delivery limits the input of maternal bacteria 
during birth and may thus be a risk factor. A positive 
association between caesarean section and food allergy 
has been reported (Eggesbo et al., 2005).
Antibiotics
Maternal use of antibiotics before and during pregnancy, 
as well as antibiotic courses during the first month of life, 
are associated with an increased risk of CMA in children 
(Metsälä et al., 2013). Antibiotic use during infancy potently 
perturbs intestinal bacteria populations and has often been 
cited as contributing factor to the rising prevalence of 
allergic disease (Blaser, 2011).
Diet
In addition to improve hygiene, the nutritional change 
that has occurred in the Western world over the past 
few decades coincides with the prevalence of atopic and 
autoimmune diseases. Interventional studies have shown 
that high fat, and low fruit and vegetables consumption is 
linked to worse allergy. A dietary basis for inflammatory 
diseases is most likely explained by interactions between 
dietary or bacterial metabolites and immune cells, or 
pathways for gut homeostasis (Thorburn et al., 2014). An 
infant diet consisting of high levels of fruits, vegetables, and 
home-prepared foods is associated with less food allergy 
by the age of 2 years (Grimshaw et al., 2014).
Animal models
Mice with FA exhibit a specific gut microbiota signature 
that is able to transmit disease susceptibility and is subject 
to reprogramming by enforced tolerance (Rivas et al., 2013). 
The allergy reducing effects of probiotics against food 
allergens have been demonstrated in murine models of FA. 
Studies with germ-free mice indicated that the interaction 
between allergens and the host’s gut microbiota plays a 
crucial role in oral tolerance development and in reducing 
secretions of allergens specific antibodies. Germ-free 
animals do not develop oral tolerance and maintain a T 
helper 2 (Th2) type immune response to oral antigens. This 
could be correct by the reconstitution of the microbiota at 
the neonatal stages, but not by reconstitution at later ages 
(McDermott and Huffnagle, 2014). These findings suggest a 
crucial role of gut microbiota for oral tolerance acquisition. 
Atarashi et al. (2013) demonstrated that mice gut 
colonisation with selected 17 Clostridia strains stimulates 
Treg cells expansion and differentiation and induces anti-
inflammatory cytokines including interleukin (IL)-10 and 
transforming growth factor (TGF)-β. Oral inoculation of 
Clostridium during the early life of conventionally reared 
mice resulted in resistance to colitis and down regulation 
of systemic immunoglobulin E responses in adult mice, 
suggesting a new therapeutic approach to allergy (Stefka 
et al., 2014). Thang et al. (2011) investigated the effects of 
LGG supplementation on mice sensitised with the whole 
CMP. LGG administration seems to favour suppression of 
the Th2 response and promotion of Th1 response (Thang 
et al., 2011).
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3. Probiotics for food allergy prevention
Most randomised controlled trials evaluated infants at 
high risk for allergy, defined as more than one family 
member having any allergic disease. Most of these studies 
looked primarily at early outcomes of allergic disease, 
such as eczema. A large number of clinical studies and 
meta-analyses have been published on this topic with 
conflicting results (Dang et al., 2013; Doege et al., 2012; 
Mugambi et al., 2012; Osborn and Sinn, 2007; Pelucchi et al., 
2012). Differences in study design, populations, probiotic 
strains and dosages are responsible for these discrepancies 
(Berni Canani and Di Costanzo, 2013b; Castellazzi et al., 
2013; Elazab et al., 2013; Ismail et al., 2013; Kim et al., 
2013; Lau, 2013). It is evident that different effects may be 
observed, depending on the strain of the microorganism 
used (Klaenhammer et al., 2012). Prenatal and postnatal 
administration of high doses of LGG seems to be the most 
promising approach (Table 1) in particular on reducing total 
immunoglobulin E (IgE) and atopic sensitisation (Elazab et 
al., 2013). Thus, carefully selection of particular probiotic 
strategy during pregnancy and early infancy is mandatory 
to obtain positive results and to limit negative outcomes. 
In fact, it has been demonstrated that the administration 
of Lactobacillus acidophilus is associated with an increased 
risk of atopic sensitisation (Elazab et al., 2013).
4. Probiotics for food allergy treatment
Administration of LGG to food allergic children (age <2 
years, challenge-proven and affected by mild to moderate 
eczema) improved the atopic eczema score significantly 
(Majama and Isolauri, 1997). A Cochrane published in 2008 
(Boyle et al., 2008), based on analysis of small numbers of 
participants, suggested that even if probiotics were not 
an effective treatment for eczema, a significant benefit 
could not be confidently excluded. Studies in infants with 
eczema who received formulas supplemented with LGG 
showed benefits in decreasing gastrointestinal symptoms 
(Isolauri et al., 2000). For instance, after a challenge study 
in infants allergic to CMP, faecal IgA levels were detected 
to be higher, and tumour necrosis factor alpha (TNF-α) 
levels were lower in the LGG applied group compared 
to placebo. Moreover, LGG is able to induce interferon-
gamma (IFN-γ) secretion in infants with CMA and IgE-
associated dermatitis, but not in infants without CMA, 
suggesting that the pattern of intestinal microbiota may 
be aberrant in infants with an atopic predisposition, and 
the beneficial effects of probiotics could be evident only 
in allergic subjects (Pohjavuori et al., 2004).
The addition of LGG to an extensively hydrolysed casein 
formula (eHCF) improved the recovery of inflamed colonic 
mucosa vs eHFC alone in infants with CMA-induced colitis, 
demonstrated with a decrease in faecal calprotectin and 
in the number of infants with positive stools occult blood 
test after 1 month (Baldassarre et al., 2010).
Apart from rapid resolution of symptoms, one of the main 
objective in FA treatment is tolerance acquisition (Tang 
and Martino, 2013). We have demonstrated that treatment 
of CMA infants with an eHFC supplemented with LGG 
accelerates oral tolerance acquisition (Berni Canani et al., 
2012b). Infants (age 1-12 months), consecutively referred 
for suspected CMA, but still receiving cow’s milk proteins, 
were invited to participate in the study. Subjects were 
randomly allocated to one of the two groups of dietary 
intervention: a control group, who received an eHCF; and 
an active group, who received eHCF containing LGG (at 
least 1.4×107 cfu/100 ml). After 12 months, the double-
blind placebo-controlled food challenge was negative in 
15 of 28 control infants (53.6%) and in 22 of 27 infants 
receiving eHCF with LGG (81.5%; P=0.027). In a subsequent 
study, otherwise healthy infants with CMA receiving eHCF, 
eHCF with LGG, hydrolysed rice formula, soy formula, or 
amino acid-based formula, were assessed after 12 months of 
dietary treatment for possible oral tolerance acquisition by 
food challenge. The rate of tolerance after 12 months was 
significantly higher in the groups receiving eHCF (43.6%) 
or eHCF plus LGG (78.9%) compared with other groups: 
hydrolysed rice formula (32.6%), soy formula (23.6%), and 
amino acid-based formula (18.2%) (Berni Canani et al., 
2013a). LGG is known to modulate immune functions via 
various pathways, including those involving enterocytes, 
monocytes, mast-cells, dendritic cells, and regulatory 
T cells (De Kivit et al., 2014). Administration of LGG is 
associated with a complex response in intestinal mucosa, 
reflected by the up- and down-regulation of several genes 
involved in the immune response, inflammation, cell-cell 
signalling, signal transcription and transduction. LGG 
alters the generation of cytokines that may be involved 
in IgE- or non-IgE-mediated CMA (i.e. IL-4, IL-5, IL-10, 
IFN-γ, TGF-β, TNF-α), and thereby can positively modulate 
the major pathways involved in CMA pathogenesis. These 
effects depend mainly on the combined activity of different 
LGG molecules (lipoteichoic acid, secreted proteins, 
exopolysaccharides, DNA) (Segers and Lebeer, 2014).
It is important to recognise that these results cannot be 
generalised to other probiotics or other Lactobacillus 
strains. Other Lactobacillus strains have different modes 
of action and varied effectiveness on immune systems. Hol 
et al. (2008) showed that supplementation of a combination 
of Lactobacillus casei CRL431 and Bifidobacterium lactis 
Bb 12 to an extensively hydrolysed CMP formula failed to 
induce tolerance during 12 months of treatment in infants 
with CMA. The differences between Lactobacillus strains 
is further demonstrated by comparative genomics studies 
that reveal that LGG contains 331 strain-specific proteins.
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Table 1. Main allergy prevention studies using probiotics.
Investigators 
•	Population / Probiotics and doses
Prenatal
administration
Postnatal
administration
Allergy preventive 
effect
Kalliomaki et al. (2001a, 2003)
•	 Mothers	with	≥1	first-degree	relative	(or	partner)	with	allergic	disease
•	 Lactobacillus rhamnosus GG (1×1010	cfu/day)	(only	to	mother	if	breast	
feeding	post-natal)
Yes, 
2-4	weeks	
before	delivery
Yes, 
6	months	(only	to	baby	if	
not	breastfeeding)
Yes, 
at	2	and	4	years
Rautava et al. (2006)
•	 Need	for	artificial	feeding	before	2	months	of	age
•	 L. rhamnosus GG (1×1010	cfu/day)	+	Bifidobacterium lactis (1×1010	cfu/
day)	added	to	infant	formula	
No Yes, 
from	<2	months	
(depending	on	age	started	
formula)	until	12	months
No
Taylor et al.	(2007);	Jensen et al. (2012)
•	 Mother	with	positive	Skin	Prick	Test	(SPT)	or	documented	allergic	disease
•	 Lactobacillus acidophilus (3×108	cfu/day)
No Yes, 
6	months	direct	to	infant
No, 
at	1	and	5	years
Kukkonen et al.	(2007);	Kuitunen et al. (2009)
•	 One	or	both	parents	with	allergic	disease
•	 L. rhamnosus	GG	and	LC705	(both	5×109	cfu	twice	daily)	+	
Bifidobacterium breve	and	Proprionibacterium freudenreichii	(both	2×109 
cfu	twice	daily)
Yes, 
2-4	weeks	
before	delivery
Yes, 
6	months	direct	to	infant
Yes,	at	2	years.	
No,	at	5	years	(except	
decrease	in	atopic	
eczema	in	caesarean-
delivered	children)
Abrahamsson et al. (2007, 2013)
•	 Families	with	allergic	disease
•	 Lactobacillus reuteri (1×108	cfu/day)
Yes, 
2-4	weeks	
before	delivery
Yes, 
12	months	direct	to	infant
No, 
at	2	and	7	years
Kopp et al. (2008)
•	 Pregnant	women	from	families	with	≥1	first-degree	relative	with	an	atopic	
disease
•	 L. rhamnosus GG (1×1010	cfu/day)	to	mother	if	breast	feeding	post-natal	
for	3	months,	than	to	the	neonates	for	additional	3	months	
Yes, 
4-6	weeks	
before	delivery
Yes, 
6	months	direct	to	infant
No, 
at	2	years
Wickens et al. (2008, 2012)
•	 One	or	both	parents	with	allergic	disease
•	 L. rhamnosus HN001 (1×1010	cfu/day)	or	B. lactis (1×1010	cfu/day)	HN019	
Yes, 
2-5	weeks	
before	delivery
Yes, 
2	years	to	infant	regardless	
of	feeding	method
Yes, 
at	2	and	4	years
Huurre et al. (2008)
•	 Mother	with	current	atopic	disease
•	 L. rhamnosus	GG	+	B. lactis (both	at	1×1010	cfu/day)
Yes, 
from	first	
trimester
Yes, 
end	of	exclusive	
breastfeeding
No
Soh et al.	(2009);	Loo	et al.	(2014)
•	 Any	first	degree	relative	with	SPT+	allergic	disease
•	 L. rhamnosus	LPR	(1×109	cfu/day)	+	Bifidobacterium longum	BL999	
(6×108	cfu/day)
No Yes, 
6	months	in	infant	formula
No, 
at	1	and	5	years
Niers et al. (2009)
•	 Atopic	disease	in	either	mother	or	father	plus	at	least	one	sibling
•	 Lactococcus lactis W58 + B. lactis W52 + Bifidobacterium bifidum W23 
(each	at:	1×109	cfu/day)
Yes, 6 weeks 
before	delivery
Yes, 
12	months	(direct	to	infant)
Yes
West et al. (2009, 2013)
•	 Atopic	disease	in	either	mother,	or	sibling
•	 Lactobacillus paracasei	strain	F19	(1×108	cfu/day	in	weaning	cereal)
No Yes, 
4-13	months	during	
weaning
Yes,	at	school-age.	
No	long-term	effects	
(8-9	years)
Dotterud et al. (2010)
•	 Unselected	population
•	 L. rhamnosus GG	+	L. acidophilus	LA5	+	B. lactis Bb-12	(each	at	5×1010 
cfu/day)
Yes, 
from	36	weeks
No, 
given	to	the	breastfeeding	
mother	for	3	months
Yes
Kim et al. (2010)
•	 Pregnant	women	with	a	family	history	of	allergic	diseases
•	B. biﬁdum	BGN4	+	B. lactis	AD011	+	L. acidophilus AD031	(each	at	
1.6×109	cfu/day)	in	0.72	g	of	maltodextrin	and	0.8	g	of	alpha-corn	
Yes, 
4-8	weeks	
before	delivery
Yes, 
6	months	after	delivery
Yes,	at	1	year
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Finally, it has been recently demonstrated that daily 
supplement of LGG resulted in a dramatic shift in the 
composition of the intestinal microbial community with a 
large increase in the number of taxa previously associated 
with a decreased risk for the development of allergy 
and atopy (Cox et al., 2010). We used high throughput 
sequencing technology (16S rRNA-based sequence analysis) 
to compare faecal samples from newly diagnosed CMA 
infants (n=12, 9 male, mean age 4.33 m) before and after 
treatment with eHCF plus LGG. Treatment with eHCF 
containing LGG, but not eHCF alone, expanded gut 
microbiota populations associated with immunoregulatory 
effects and increased butyrate production at intestinal 
level. We found a significant positive correlations between 
faecal butyrate concentration and the abundance of four 
clostridia genera: Faecalibacterium, Blautia, Roseburia, 
and Coprococcus. All four genera resulted increased in 
CMA infants after treatment with eHCF plus LGG. A 
protective role for butyrate was also confirmed in a murine 
model of CMA. C3H/HeOuJ mice pretreated for 2 weeks 
with butyrate (20 mg/kg/d) before oral sensitisation with 
beta-lactoglobulin (20 mg) showed a significant reduction 
of sIgE and IL-4 production (Berni Canani et al., 2014). 
Our data suggests that eHCF containing LGG promotes 
tolerance in infants with CMA, in part, through its influence 
on the community structure of the gut microbiota, this 
mechanism acts in combination with the activity of LGG 
immunoregulatory components (Figure 1). These data 
support the importance of a ‘nutritional immunology 
approach’ able not only to efficiently cure the symptoms, 
but also to accelerate tolerance acquisition (Cao et al., 2014; 
Nermes et al., 2013).
Investigators 
•	Population / Probiotics and doses
Prenatal
administration
Postnatal
administration
Allergy preventive 
effect
Boyle	et al.	(2011)
•	 Pregnant	women	carrying	infants	at	high	risk	of	allergic	disease
•	 L. rhamnosus	GG	(1.8×1010	cfu/day)
Yes, 
from	36	weeks	
gestation	until	
delivery
No No,	at	1	year
Rautava et al. (2012)
•	 Mothers	with	allergic	disease	and	atopic	sensitisation
•	 L. rhamnosus	LPR	+	B. longum BL999	or	L. paracasei	ST11	+	B. longum 
BL999	(each	at	1×109	cfu/day)
Yes, 
2	months	
before	delivery
Yes, 
2	months	of	breast	feeding
Yes
Allen et al. (2014)
•	 Unselected	population
•	 Lactobacillus salivarius CUL61 (6.25×109	cfu/day)	+	L. paracasei	CUL08	
(1.25×109	cfu/day)	+	Bifidobacterium animalis ssp. lactis	CUL34	(1.25×109 
cfu/day)	+	B. bifidum	CUL20	(1.25×109	cfu/day)
Yes, 
from	36	weeks	
gestation	until	
delivery
Yes, 
6	months	direct	to	infant
Yes, 
at	6	months	and	2	
years
Tabel 1. Continued.
Gut microbiota 
modulation 
LGG
LGG specific 
components
SCFAs
(butyrate)
production
Immunomodulation:
• Induction regulatory Tcells
• Th1 response
• Anti-inflammatory cytokines
Oral tolerance 
induction 
Figure 1. The multiple mechanisms elicited by the probiotic Lactobacillus rhamnosus GG (LGG) in inducing oral tolerance acquisition 
in children affected by food allergy. There is a synergistic effect mediated by immunoregulatory components of L. rhamnosus 
GG, and its efficacy in regulating composition and function of gut microbiota. An increased production of butyrate deriving from 
the gut microbiota composition shaping is able through a direct interaction with the immune system to stimulate a Th1 response.
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5. Conclusions
It is becoming clear that the composition and metabolic 
activity of the intestinal microbiome exerts a crucial 
influence on immune development and function. These 
findings are contributing to a better knowledge in the 
FA pathogenesis and are opening new preventive and 
therapeutic strategies. There is an extensive literature 
documenting the efficacy of LGG for prevention and 
treatment of food allergy. We are understanding the 
mechanisms elicited by LGG, and its metabolites, 
in influencing food allergen sensitisation. A deeper 
understanding of these mechanisms is opening the way 
to new immunotherapeutic strategies for children affected 
by FA that can efficiently limit the disease burden.
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